Although the trial did not demonstrate a benefit in either overall or progression-free survival, it remains unclear whether PD-1 blockade induces measurable biological responses in the tumor or immune microenvironment—insights that could help explain the lack of clinical efficacy and guide future strategies. The gene discussed is PDCD1; the disease is neoplasm.